From the publishers of JADPRO

Graft-vs.-Host Disease Resource Center

Advertisement

OncLive

Axatilimab meets ORR end point in chronic GVHD after 2 or more prior lines of therapy

Bone Marrow Transplantation

Predictors and significance of kidney dysfunction in patients with chronic graft-versus-host disease

Blood

Novel developments in the prophylaxis and treatment of acute GVHD

Annals of Hematology

Ruxolitinib versus basiliximab for steroid-refractory acute graft-versus-host disease: A retrospective study

Blood Advances

Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD

Blood Cell Therapy

Novel insights into GVHD and immune reconstitution after allogeneic hematopoietic cell transplantation

Cancers

Graft-versus-host disease prophylaxis with antithymocyte globulin in patients receiving stem cell transplantation from unrelated donors: An observational retrospective single-center study

Blood Cell Therapy

Novel insights into GVHD and immune reconstitution after allogeneic hematopoietic cell transplantation

Blood Advances

Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD

The New England Journal of Medicine

Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis

JAMA Open Network

Analysis of antibiotic exposure and development of acute graft-vs-host disease following allogeneic hematopoietic cell transplantation

Blood

Prognostic value of blood biomarkers in steroid-refractory or steroid-dependent acute graft-versus-host disease: a REACH2 analysis

Blood Cell Therapy

Utility of eGVHD App for bedside GVHD assessment in a high-volume BMT center

Annals of Hematology

Safety and efficacy of mesenchymal stromal cell therapy for multi-drug-resistant acute and late-acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation

Transplantation and Cellular Therapy

Impact of chronic graft-versus-host disease (GVHD) on patients’ employment, income, and informal caregiver burden: Findings from the Living with Chronic GVHD Patient Survey

Indian Journal of Ophthalmology

Dry eye disease and risk factors for corneal complications in chronic ocular graft-versus-host disease

Translation and Cellular Therapy

Impact of conditioning regimen and graft-versus-host disease prophylaxis on the outcome of haploidentical peripheral blood stem cell transplantation for high-risk severe aplastic anaemia in children and young adults

Frontiers in Medicine

Post-transplantation cyclophosphamide combined with tacrolimus and low-dose post-engraftment anti-thymoglobulin as GVHD prophylaxis for patients undergoing peripheral blood stem cell transplantation from haploidentical family donor: A single center analysis

Frontiers in Immunology

Exosomes, MDSCs and Tregs: A new frontier for GVHD prevention and treatment

Critical Reviews in Oncology/Hematology

Recent advances and research progress in biomarkers for chronic graft versus host disease

Clinical Advances in Hematology & Oncology

Highlights in graft-versus-host disease from the 2023 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR

Translation and Cellular Therapy

A phase I trial of SYK inhibition with fostamatinib in the prevention and treatment of chronic graft-versus-host disease

Blood

Phase II clinical trial evaluating abatacept in patients with steroid-refractory chronic graft versus host disease

JAMA Dermatology

Prognostic value of cutaneous disease severity estimates on survival outcomes in patients with chronic graft-vs-host disease

Transplantation and Cellular Therapy

Frailty in patients with chronic graft-versus-host disease

Nature

Pediatric chronic graft-versus-host disease-related dry eye disease and the diagnostic association of potential clinical findings

Transplantation and Cellular Therapy

Extracorporeal photopheresis as graft-versus-host disease prophylaxis: A randomized controlled trial

Blood

Effective treatment of low-risk acute GVHD with itacitinib monotherapy

Transplantation and Cellular Therapy

A Calcineurin Inhibitor Free Graft Versus Host Disease Prophylaxis for Patients Undergoing Matched Related and Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplant

Journal of Clinical Oncology

Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study

Transplantation and Cellular Therapy

A Multiparameter Prognostic Risk Score of Chronic GVHD based on CXCL10 and Plasmacytoid DC (pDC) levels in the Peripheral Blood at 3 months after Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Blood

Prognostic Value of Blood Biomarkers in Steroid-Refractory/Dependent Acute Graft-vs-Host Disease: A REACH2 Analysis

Hematologist: ASH News and Publications

For patients facing chronic GvHD, 2022 was a breakthrough year

Bone Marrow Transplantation

Nilotinib efficacy and safety as salvage treatment following imatinib intolerance and/or inefficacy in steroid refractory chronic graft-versus-host-disease (SR-cGVHD)

Transplantation and Cellular Therapy

Chronic graft-versus-host-disease treatment in Brazil: analyses of failure-free survival

Transplantation and Cellular Therapy

Pericardial effusion as a purported manifestation of graft versus host disease following allogeneic hematopoietic cell transplantation

Blood

How I prevent GVHD in high-risk patients: posttransplant cyclophosphamide and beyond

2022 ASH Annual Meeting

A Real-World Evidence Comparison of 1-Year Overall Survival and Relapse-Free Survival between Patients Treated with Abatacept in Combination with a Calcineurin Inhibitor and Methotrexate Versus Antithymocyte Globulin or Post-Transplant Cyclophosphamide Following alloHCT

Journal of Clinical Oncology

Axatilimab for Chronic Graft-Versus-Host Disease After Failure of at Least Two Prior Systemic Therapies: Results of a Phase I/II Study

Blood

Prevention of acute GVHD disease using an orthogonal IL-2/IL-2Rβ system to selectively expand regulatory T-cells in vivo

Blood

Effective treatment of low risk acute GVHD with itacitinib monotherapy

Oncologist

Recent FDA Approvals in the Treatment of Graft-Versus-Host Disease

2022 ASH Annual Meeting

363 Phase I/II Clinical Trials of Donor-Derived Purified Regulatory T Cells for the Treatment of Steroid-Refractory Chronic Graft Versus Host Disease

2022 ASH Annual Meeting

574 Addition of Ruxolitinb to Corticosteroids As First-Line Therapy for High-Risk Acute Graft Versus Host Disease in Allogeneic Peripheral Blood Stem Cell Transplantation

2022 ASH Annual Meeting

265 Precision-Engineered Cell Therapy Orca-T Demonstrates High Relapse-Free Survival at 1 Year While Reducing Graft-Versus-Host Disease and Toxicity

2022 ASH Annual Meeting

LBA-4 Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil As the New Standard for Graft-Versus-Host Disease (GVHD) Prophylaxis in Reduced Intensity Conditioning: Results from Phase III BMT CTN 1703

Transplantation and Cellular Therapy

Humoral and Cellular Immune Response to Covid-19 Vaccination in Patients with Chronic Graft-versus-Host Disease on Immunosuppression

Journal of Clinical Oncology

Burden of Long-Term Morbidity Borne by Survivors of Acute Myeloid Leukemia Treated With Blood or Marrow Transplantation: The Results of the BMT Survivor Study

Nature

Interstitial lung diseases after hematopoietic stem cell transplantation: New pattern of lung chronic graft-versus-host disease?

Transplantation and Cellular Therapy

Profiling the fungal microbiome after FMT for graft-versus-host disease: insights from a phase 1 interventional study

Blood

A diagnostic classifier for pediatric chronic graft-versus-host disease: results of the ABLE / PBMTC 1202 study

Transplantation and Cellular Therapy

Desiccating Stress Significantly Increases the Risk for Chronic Ocular Graft-versus-Host-Disease

Blood

Effective treatment of low risk acute GVHD with itacitinib monotherapy

Transplantation and Cellular Therapy

Late Effects of Severe Acute Graft-versus-Host Disease on Quality of Life, Medical Comorbidities, and Survival

Blood

MicroRNA serum profiles and chronic graft-versus-host disease

Nature

Safety and efficacy of fecal microbiota transplantation in the treatment of graft-versus-host disease

Transplantation and Cellular Therapy

Healthcare resource utilization and costs of steroid-associated complications in patients with graft-versus-host disease

Transplantation and Cellular Therapy

Post-transplantation cyclophosphamide vs tacrolimus and methotrexate graft-versus-host disease prophylaxis for HLA-matched donor transplantation

Nature

Disease progression, treatments, hospitalization, and clinical outcomes in acute GVHD: a multicenter chart review

Blood Advances

Organ-specific response after low-dose interleukin-2 therapy for steroid-refractory chronic graft-versus-host disease

Nature

Long-term clinical outcomes and predictive factors in patients with chronic ocular graft-versus-host disease

Blood Advances

Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial

Journal of Clinical Medicine

Impact of Cryopreservation of Peripheral Blood Stem Cells (PBSC) in Transplantation from Matched Unrelated Donor (MUD)

Clinical Cancer Research

FDA Approval Summary: Belumosudil for Adult and Pediatric Patients 12 Years and Older with Chronic GvHD after Two or More Prior Lines of Systemic Therapy

Clinical and Experimental Optometry

Keeping an 'eye' on ocular GVHD

Transplantation and Cellular Therapy

Neuropathy and Muscle Cramps in Autologous and Allogeneic Hematopoietic Cell Transplantation Survivors

Transplantation and Cellular Therapy

Correlation of patient-reported outcomes with clinical organ responses: data from the Belumosudil chronic graft-versus-host disease studies

JCO Oncology Practice

Health literacy and clinical outcomes following hematopoietic stem-cell transplantation

Blood Advances

Prospective external validation of biomarkers to predict acute graft-versus host disease severity

Transplantation and Cellular Therapy

Low-intensity immunosuppressive therapy for chronic graft-versus-host disease

Blood Advances

Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification

Transplant and Cellular Therapy

Toward a Better Understanding of the Atypical Features of Chronic Graft-Versus-Host Disease: A Report from the 2020 National Institutes of Health Consensus Project Task Force

ASCO Annual Meeting

Ruxolitinib in chronic steroid-refractory graft-versus-host-disease

JAMA

Reducing graft-vs-host disease in blood stem cell transplants

Blood

Dual inhibition of the MEK/ERK and PI3K/AKT pathways prevents pulmonary GVHD suppressing perivenulitis and bronchiolitis

Blood Advances

Prediction of outcomes after second-line treatment for acute graft-versus-host disease

ASCO Annual Meeting

Incidence of chronic graft versus host disease using post-transplant cyclophosphamide in HLA-matched versus haploidentical donors

Targeted Oncology

Acute GVHD responds quickly to itolizumab treatment in phase 1b trial

Transplantation and Cellular Therapy

Healthcare resource utilization and costs of steroid-associated complications in patients with graft-versus-host disease

Journal of Clinical Oncology

Naive T-cell depletion to prevent chronic graft-versus-host disease

Blood

A phase 1 study of donor regulatory T-cell infusion plus low-dose interleukin-2 for steroid-refractory chronic graft-vs-host disease

The ASCO Post

Abatacept for prophylaxis of acute graft-vs-host disease

Management of Chronic Oral GVHD in Patient with High-Risk AML and Mixed Chimerism

Patient With History of Acute Steroid-Dependent Skin GVHD Develops Chronic GVHD: Part 2

Patient With History of Acute Steroid-Dependent Skin GVHD Develops Chronic GVHD: Part 1